what is t-cell rich lymphoma?
- Anonymous1 decade agoFavorite Answer
Lymphoma - non-Hodgkin's; Lymphocytic lymphoma; Histiocytic lymphoma; Lymphoblastic lymphoma; Cancer - non-Hodgkin's lymphoma
Causes, incidence, and risk factors
Non-Hodgkin's lymphomas can be slow-growing (low-grade) or rapidly growing (high-grade) cancer. For most patients, the cause is unknown, but lymphomas may develop in people with suppressed immune systems as a result of organ transplantation, for instance.
The tumors are graded according to their level of malignancy (aggressiveness)-- low-grade, intermediate-grade or high-grade. Burkitt's tumor is an example of a high-grade lymphoma. Non-Hodgkin's tumors occur more frequently than Hodgkin's lymphoma.
Usually, non-Hodgkin's lymphomas affect people older than 50. High-risk groups include organ transplant recipients and immunosuppressed people. The incidence is 3 in 10,000 people.
Enlarged lymph nodes (such as an armpit lump), isolated or widespread
Excessive sweating, with night sweats
Unintentional weight loss
Additional symptoms that may be associated with this disease include flank pain.
Signs and tests
Tests that may indicate non-Hodgkin's lymphoma include:
A peripheral blood smear showing abnormal white blood cells
A CBC with differential
A lymph node biopsy
A bone marrow biopsy
A staging evaluation (tumor staging) to determine the extent of the disease includes:
A physical examination
CT scans of the chest, abdomen and pelvis
An exploratory laparotomy or liver biopsy
Blood chemistry tests
MRI or other x-ray study may also be performed
A PET scan, (positron emission test)
This disease may also alter the results of the following tests:
A gallium (Ga.) scan
An immunoelectrophoresis - serum test
A quantitative immunoglobulins (nephelometry) test
A mononucleosis spot test
Treatment depends upon the stage of the disease. Low-grade disease may just need to be observed with no treatment until it causes problems (early treatment is not more effective). When treatment becomes necessary, chemotherapy or radiation therapy may be used. Patients with more aggressive or resistant disease may require more intensive treatment. High-dose chemotherapy with bone marrow transplantation may be a treatment option in selected cases.
The stress of illness may be eased by joining a support group whose members share common experiences and problems. See cancer - support group.
The average survival is 6 to 8 years for patients with low-grade lymphoma. The outcome for patients with high-grade lymphoma depends upon the response to chemotherapy or other treatment, and the type of high-grade lymphoma. About 30% of adults with high-grade lymphoma are permanently cured.
Infections resulting from immune suppression from chemotherapy or radiation therapy, or low gamma globulin secondary to disease
Autoimmune hemolytic anemia
T-cell rich B-cell non-Hodgkin's lymphoma (T-cell rich B-cell lymphoma) is a morphological variant of diffuse large B-cell lymphoma. It is important to recognize this variant in the differential diagnosis of T-cell non-Hodgkin's lymphoma. The main differential diagnosis of T-cell rich B-cell lymphoma, nodular and diffuse lymphocyte predominance Hodgkin's disease (lymphocyte predominance Hodgkin's disease). is, however, even more difficult and differentiating criteria are still not satisfactorily defined. Moreover, T-cell rich B-cell lymphoma may not represent a clinicopathological entity. Twelve cases of T-cell rich B-cell lymphoma, selected on the basis of morphology and limited immunohistochemistry without previous knowledge of clinical data, were studied by immunohistochemistry and polymerase chain reaction for bcl-2 rearrangements to investigate the histogenetic background. In three of 12 cases, bcl-2 rearrangements were found, strongly suggesting a follicle centre cell origin. In three other cases, a documented history of definite nodular lymphocyte predominance Hodgkin's disease 29 months to 20 years prior to the diagnosis of the lymphoma was present. No differences in growth pattern, residual nodularity, tumour cell distribution, cellular morphology and composition, or immunophenotypical differences were noted in these six cases as compared to the remaining cases. These data underscore the histogenetic diversity in T-cell rich B-cell lymphoma and identify it as a progressed form of lymphoma derived from entities as diverse as follicle centre cell lymphoma and nodular lymphocyte predominance Hodgkin's disease. Moreover, it shows a complete morphological overlap with the diffuse form of lymphocyte predominance Hodgkin's disease and may actually encompass this disease entity.